<DOC>
	<DOC>NCT02708082</DOC>
	<brief_summary>Study consists of five visits over a one to three month time period.</brief_summary>
	<brief_title>Glaucoma HFA / OCT Specificity Study</brief_title>
	<detailed_description>Each visit consists of optical coherence tomography (OCT) scanning (4 scans ) and two HFA (Humphrey Field Analyzer) visual fields of the study eye only.</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<criteria>Adult males or females 40 to 80 years old Able and willing to attend the required study visits Able and willing to provide consent and follow study instructions in English A diagnosis by the Principal Investigator or coinvestigator of glaucoma, preperimetric glaucoma or glaucoma suspect Subjects must have experience in threshold automated perimetry, having performed a previous SITA (Swedish Interactive Thresholding Algorithm) threshold test within one year of enrolling to the study Ability to fixate that allows obtaining acceptable visual fields and OCT scans in the study eye â€¢ Bestcorrected visual acuity less than 20/40 (study eye only) on a Snellen chart or on a Snellen equivalent acuity chart Spherical refraction outside 12.00 to +5.00 diopters (D) or cylinder correction outside 3.00 D (study eye only) Amblyopia (either eye) Narrow iridocorneal angles or a diagnosis of narrow angle glaucoma Previous or current eye disease in the study eye, serious eye trauma or intraocular surgery (except cataracts with lens implants), or the presence of ocular findings that could affect the visual field, other than glaucoma Cataract surgery in the study eye within six (6) months of first visit Dx of any optic neuropathy other than glaucoma Vitreoretinal traction or epiretinal membrane in the study eye Diagnosis or history of any systemic disease / condition / treatment which is likely to affect the visual field outcome in the Study Eye other than glaucoma History of diabetes, leukemia, AIDS, uncontrolled systemic high blood pressure, dementia or multiple sclerosis Any disease that is likely to progress within the 3 month time period that might have visual field implications A life threatening or debilitating disease Participation in any study involving a nonFDA approved investigational drug (IND) within the past month, or ongoing participation in a study with a nonFDA approved or cleared investigational device (IDE) Concomitant use of hydrochloroquine and/or chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>